rotigotine vs Rotigotine (LY03003)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: Dopamine receptors · full Parkinson's Disease pipeline
rotigotine · Neupro
Marketed by UCB and partners
NCT00244387 · Phase 3 · completed
Although the registry reports a randomized, double-blind design with 506 participants, it lists no comparator arm, so the treatment cannot be evaluated against another treatment or placebo from the available record. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Reported efficacy
Unified Parkinson's Disease Rating Score (UPDRS) Part 3 Sum Score (baseline, 16 weeks after dosing): UPDRS Part III change at 16 weeks, rotigotine vs placebo: -6.4 ± 1.2 (95% CI -8.7 to -4.1; p<0.001); non-inferior to ropinirole (n=420). (met)
Result source: NCT01628926
Rotigotine (LY03003) · Jinyouping
Marketed by Luye Pharma Group
NCT04571164 · Phase 3 · completed
The Phase 3 trial randomised 294 patients with early Parkinson's disease (147 per arm) to LY03003 or placebo with quadruple masking. A conference abstract reports that the primary endpoint, change in UPDRS II+III at 24 weeks, favoured LY03003 (-11.8 vs -5.6, P<0.001). The registry has no posted results and no peer-reviewed paper was found.
Result from a conference abstract (International Congress of Parkinson's Disease and Movement Disorders, 2025), not from the registry or a peer-reviewed publication.
Reported efficacy
Change from baseline to the end of the treatment period in the Unified Parkinson's Disease Rating Scale(UPDRS)part(Ⅱ+Ⅲ)Total Score (From baseline to the end of the double-blind dose maintenance period at 24weeks): Change from baseline in UPDRS Part II+III total score: LY03003 -11.8 vs placebo -5.6 (P<0.001) (met)
Result source: NCT04571164
Results for Parkinson's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.
| Key endpoint | rotigotine | Rotigotine (LY03003) |
|---|---|---|
| OFF time, change | -2.1 vs -0.7−1.4 vs placeboNCT01628848 | —Not posted · NCT04571164 |
| ON time without troublesome dyskinesia, change | —Not posted · NCT00243971 | —Not posted · NCT04571164 |
| UPDRS Part III, change | -10.9 vs -4.5−6.4 vs placeboNCT016289263 other results
| —Not posted · NCT04571164 |
| MDS-UPDRS Part II, change | —Not posted · NCT00243971 | —Not posted · NCT04571164 |
OFF time, change
- rotigotine
- -2.1 vs -0.7−1.4 vs placeboNCT01628848
- Rotigotine (LY03003)
- —Not posted · NCT04571164
ON time without troublesome dyskinesia, change
- rotigotine
- —Not posted · NCT00243971
- Rotigotine (LY03003)
- —Not posted · NCT04571164
UPDRS Part III, change
- rotigotine
- -10.9 vs -4.5−6.4 vs placeboNCT01628926
3 other results
- -9.9 vs -5.3 NCT01628926
- -9.7 vs -5.5 NCT01628926
- -10.1 vs -4.4 NCT01628848
- Rotigotine (LY03003)
- —Not posted · NCT04571164
MDS-UPDRS Part II, change
- rotigotine
- —Not posted · NCT00243971
- Rotigotine (LY03003)
- —Not posted · NCT04571164
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. rotigotine: 4 of 4 rows · Rotigotine (LY03003): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | rotigotine | Rotigotine (LY03003) |
|---|---|---|
| Dropout rate | 15.5%a NCT01628926 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 show 33 more results19% NCT01523301 · Phase 4 · registry result, not featured evidence 9.8%high dose NCT01782222 · Phase 4 · registry result, not featured evidence 26.8%low dose NCT01782222 · Phase 4 · registry result, not featured evidence 5.7% NCT01744496 · Phase 4 · registry result, not featured evidence 9.2% NCT01711866 · Phase 4 · registry result, not featured evidence 19.6% NCT01300819 · Phase 4 · registry result, not featured evidence 21.4% NCT00594464 · Phase 4 · registry result, not featured evidence 8% NCT01646255 · Phase 3 · registry result, not featured evidence 8.9% NCT01646268 · Phase 3 · registry result, not featured evidence 12.2% NCT01723904 · Phase 3 · registry result, not featured evidence 20.2% NCT01631825 · Phase 3 · registry result, not featured evidence 14.9%8 mg/24 hr NCT00522379 · Phase 3 · registry result, not featured evidence 21.2%6 mg/24 hr NCT00522379 · Phase 3 · registry result, not featured evidence 21.5%4 mg/24 hr NCT00522379 · Phase 3 · registry result, not featured evidence 21.8%2 mg/24 hr NCT00522379 · Phase 3 · registry result, not featured evidence 12.6% NCT00474058 · Phase 3 · registry result, not featured evidence 52.2% NCT00501969 · Phase 3 · registry result, not featured evidence 51.1% NCT00505687 · Phase 3 · registry result, not featured evidence n/a: no completion milestone NCT00594386 · Phase 3 · registry result, not featured evidence n/a: no completion milestone NCT00599196 · Phase 3 · registry result, not featured evidence n/a: no completion milestone NCT00594165 · Phase 3 · registry result, not featured evidence 21.8% NCT00593606 · Phase 3 · registry result, not featured evidence 34.3% NCT01628965 · Phase 2/3 · registry result, not featured evidence 16.7% NCT00537485 · Phase 2/3 · registry result, not featured evidence 28.5% NCT01631812 · Phase 2 · registry result, not featured evidence 13.8% NCT01628848 · Phase 2 · registry result, not featured evidence 0%1 Puff NCT00296192 · Phase 2 · registry result, not featured evidence 0%2 Puffs NCT00296192 · Phase 2 · registry result, not featured evidence 0%3 Puffs NCT00296192 · Phase 2 · registry result, not featured evidence 0%4 Puffs NCT00296192 · Phase 2 · registry result, not featured evidence 11.6%Advanced Parkinson's Disease NCT01634243 · Phase 2 · registry result, not featured evidence 28.6%Early-stage Parkinson's Disease NCT01634243 · Phase 2 · registry result, not featured evidence — NCT00292227 · Phase 1 · registry result, not featured evidence | — |
| Discontinued due to AEs | 7.7%a NCT01628926 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 show 33 more results13.6% NCT01523301 · Phase 4 · registry result, not featured evidence 7.3%high dose NCT01782222 · Phase 4 · registry result, not featured evidence 12.2%low dose NCT01782222 · Phase 4 · registry result, not featured evidence 2.9% NCT01744496 · Phase 4 · registry result, not featured evidence 2.3% NCT01711866 · Phase 4 · registry result, not featured evidence 12.1% NCT01300819 · Phase 4 · registry result, not featured evidence — NCT00594464 · Phase 4 · registry result, not featured evidence 4.6% NCT01646255 · Phase 3 · registry result, not featured evidence 4.8% NCT01646268 · Phase 3 · registry result, not featured evidence 5.6% NCT01723904 · Phase 3 · registry result, not featured evidence 13.1% NCT01631825 · Phase 3 · registry result, not featured evidence 5.3%8 mg/24 hr NCT00522379 · Phase 3 · registry result, not featured evidence 11.5%6 mg/24 hr NCT00522379 · Phase 3 · registry result, not featured evidence 14%4 mg/24 hr NCT00522379 · Phase 3 · registry result, not featured evidence 11.9%2 mg/24 hr NCT00522379 · Phase 3 · registry result, not featured evidence 5.8% NCT00474058 · Phase 3 · registry result, not featured evidence 19.2% NCT00501969 · Phase 3 · registry result, not featured evidence 25.8% NCT00505687 · Phase 3 · registry result, not featured evidence 26.4% NCT00594386 · Phase 3 · registry result, not featured evidence 24.4% NCT00599196 · Phase 3 · registry result, not featured evidence 24% NCT00594165 · Phase 3 · registry result, not featured evidence 10.5% NCT00593606 · Phase 3 · registry result, not featured evidence 21% NCT01628965 · Phase 2/3 · registry result, not featured evidence 11.1% NCT00537485 · Phase 2/3 · registry result, not featured evidence 19.2% NCT01631812 · Phase 2 · registry result, not featured evidence 10.3% NCT01628848 · Phase 2 · registry result, not featured evidence —1 Puff NCT00296192 · Phase 2 · registry result, not featured evidence —2 Puffs NCT00296192 · Phase 2 · registry result, not featured evidence —3 Puffs NCT00296192 · Phase 2 · registry result, not featured evidence —4 Puffs NCT00296192 · Phase 2 · registry result, not featured evidence 11.6%Advanced Parkinson's Disease NCT01634243 · Phase 2 · registry result, not featured evidence 23.8%Early-stage Parkinson's Disease NCT01634243 · Phase 2 · registry result, not featured evidence — NCT00292227 · Phase 1 · registry result, not featured evidence | — |
| Serious AEs | 4.2%a NCT01628926 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 show 33 more results3.3% NCT01523301 · Phase 4 · registry result, not featured evidence 2.4%high dose NCT01782222 · Phase 4 · registry result, not featured evidence 4.9%low dose NCT01782222 · Phase 4 · registry result, not featured evidence 5.7% NCT01744496 · Phase 4 · registry result, not featured evidence 1.1% NCT01711866 · Phase 4 · registry result, not featured evidence 3.6% NCT01300819 · Phase 4 · registry result, not featured evidence 28.6% NCT00594464 · Phase 4 · registry result, not featured evidence 3.4% NCT01646255 · Phase 3 · registry result, not featured evidence 4.8% NCT01646268 · Phase 3 · registry result, not featured evidence 5.6% NCT01723904 · Phase 3 · registry result, not featured evidence 10.6% NCT01631825 · Phase 3 · registry result, not featured evidence 0%8 mg/24 hr NCT00522379 · Phase 3 · registry result, not featured evidence 1.9%6 mg/24 hr NCT00522379 · Phase 3 · registry result, not featured evidence 2.8%4 mg/24 hr NCT00522379 · Phase 3 · registry result, not featured evidence 4%2 mg/24 hr NCT00522379 · Phase 3 · registry result, not featured evidence 5.2% NCT00474058 · Phase 3 · registry result, not featured evidence 37.5% NCT00501969 · Phase 3 · registry result, not featured evidence 24.2% NCT00505687 · Phase 3 · registry result, not featured evidence 64% NCT00594386 · Phase 3 · registry result, not featured evidence 34.5% NCT00599196 · Phase 3 · registry result, not featured evidence 47.2% NCT00594165 · Phase 3 · registry result, not featured evidence 0% NCT00593606 · Phase 3 · registry result, not featured evidence 16.8% NCT01628965 · Phase 2/3 · registry result, not featured evidence 2.2% NCT00537485 · Phase 2/3 · registry result, not featured evidence 13.1% NCT01631812 · Phase 2 · registry result, not featured evidence 3.4% NCT01628848 · Phase 2 · registry result, not featured evidence 0%1 Puff NCT00296192 · Phase 2 · registry result, not featured evidence 5.9%2 Puffs NCT00296192 · Phase 2 · registry result, not featured evidence 0%3 Puffs NCT00296192 · Phase 2 · registry result, not featured evidence 5.9%4 Puffs NCT00296192 · Phase 2 · registry result, not featured evidence 7%Advanced Parkinson's Disease NCT01634243 · Phase 2 · registry result, not featured evidence 4.8%Early-stage Parkinson's Disease NCT01634243 · Phase 2 · registry result, not featured evidence 0% NCT00292227 · Phase 1 · registry result, not featured evidence | — |
| Most frequent reported AEs | a application site reaction 54.2% (placebo 11.8%) nasopharyngitis 16.7% (placebo 15.3%) dyskinesia 16.1% (placebo 1.2%) NCT01628926 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 show 33 more resultsnausea 22.8% (placebo 7.7%) dizziness 15.2% (placebo 12.8%) suicidal ideation 11.4% (placebo 11.2%) NCT01523301 · Phase 4 · registry result, not featured evidence high dose somnolence 9.8% (placebo 7.5%) constipation 7.3% (placebo 2.5%) dry mouth 7.3% (placebo 0%) NCT01782222 · Phase 4 · registry result, not featured evidence low dose application site pruritus 9.8% (placebo 5%) depression 9.8% (placebo 5%) nausea 9.8% (placebo 10%) NCT01782222 · Phase 4 · registry result, not featured evidence nausea 22.9% (placebo 6.1%) headache 17.1% (placebo 12.1%) application site erythema 8.6% (placebo 0%) NCT01744496 · Phase 4 · registry result, not featured evidence application site pruritus 10.3% application site erythema 6.9% dizziness 6.9% NCT01711866 · Phase 4 · registry result, not featured evidence nausea 12.1% (placebo 5.6%) somnolence 8.1% (placebo 5.6%) application site pruritus 6.7% (placebo 1.6%) NCT01300819 · Phase 4 · registry result, not featured evidence procedural pain 35.7% constipation 21.4% nausea 21.4% NCT00594464 · Phase 4 · registry result, not featured evidence dizziness 10.9% (placebo 4.1%) nausea 9.2% (placebo 1.2%) pruritus 8% (placebo 5.8%) NCT01646255 · Phase 3 · registry result, not featured evidence nausea 8.9% (placebo 3.3%) dizziness 8.1% (placebo 5.7%) pruritus 8.1% (placebo 4.1%) NCT01646268 · Phase 3 · registry result, not featured evidence application site pruritus 13.3% dizziness 10% orthostatic hypotension 10% NCT01723904 · Phase 3 · registry result, not featured evidence application site reaction 61.7% nasopharyngitis 23.7% dyskinesia 15.6% NCT01631825 · Phase 3 · registry result, not featured evidence 8 mg/24 hr dyskinesia 14.9% (placebo 2.8%) nausea 11.7% (placebo 7.4%) headache 8.5% (placebo 11.1%) NCT00522379 · Phase 3 · registry result, not featured evidence 6 mg/24 hr nausea 14.4% (placebo 7.4%) dyskinesia 10.6% (placebo 2.8%) application site pruritus 7.7% (placebo 1.9%) NCT00522379 · Phase 3 · registry result, not featured evidence 4 mg/24 hr dizziness 10.3% (placebo 8.3%) nausea 10.3% (placebo 7.4%) headache 7.5% (placebo 11.1%) NCT00522379 · Phase 3 · registry result, not featured evidence 2 mg/24 hr nausea 12.9% (placebo 7.4%) headache 9.9% (placebo 11.1%) dizziness 7.9% (placebo 8.3%) NCT00522379 · Phase 3 · registry result, not featured evidence nausea 21.5% (placebo 9.4%) dizziness 10.5% (placebo 6.3%) dyskinesia 7.9% (placebo 4.2%) NCT00474058 · Phase 3 · registry result, not featured evidence somnolence 33.7% fall 15.4% dyskinesia 13.9% NCT00501969 · Phase 3 · registry result, not featured evidence somnolence 28% oedema peripheral 19.4% fall 15.6% NCT00505687 · Phase 3 · registry result, not featured evidence somnolence 58.1% fall 38.8% oedema peripheral 31% NCT00594386 · Phase 3 · registry result, not featured evidence somnolence 38.4% nausea 18.9% oedema peripheral 18.7% NCT00599196 · Phase 3 · registry result, not featured evidence somnolence 53.7% oedema peripheral 36.6% fall 31.9% NCT00594165 · Phase 3 · registry result, not featured evidence application site reaction 67.1% nausea 32.9% nasopharyngitis 18.2% NCT01628965 · Phase 2/3 · registry result, not featured evidence application site reaction 46.7% (placebo 22.2%) nausea 23.3% (placebo 5.6%) vomiting 15.6% (placebo 1.1%) NCT00537485 · Phase 2/3 · registry result, not featured evidence application site reaction 51.5% nasopharyngitis 20.8% dyskinesia 16.2% NCT01631812 · Phase 2 · registry result, not featured evidence application site reaction 50.6% (placebo 18.4%) nasopharyngitis 20.7% (placebo 14.9%) nausea 19.5% (placebo 5.7%) NCT01628848 · Phase 2 · registry result, not featured evidence 1 Puff somnolence 11.8% (placebo 7.7%) application site dryness 5.9% (placebo 0%) application site irritation 5.9% (placebo 0%) NCT00296192 · Phase 2 · registry result, not featured evidence 2 Puffs application site reaction 17.6% (placebo 0%) somnolence 11.8% (placebo 7.7%) back pain 5.9% (placebo 0%) NCT00296192 · Phase 2 · registry result, not featured evidence 3 Puffs somnolence 16.7% (placebo 7.7%) application site irritation 11.1% (placebo 0%) dizziness 5.6% (placebo 7.7%) NCT00296192 · Phase 2 · registry result, not featured evidence 4 Puffs dizziness 17.6% (placebo 7.7%) nausea 17.6% (placebo 15.4%) application site reaction 11.8% (placebo 0%) NCT00296192 · Phase 2 · registry result, not featured evidence administration site reaction 46.5% nausea 20.9% somnolence 16.3% NCT01634243 · Phase 2 · registry result, not featured evidence administration site reaction 76.2% nausea 38.1% nasopharyngitis 28.6% NCT01634243 · Phase 2 · registry result, not featured evidence nausea 42.4% (placebo 21.9%) dizziness 28.8% (placebo 9.4%) headache 28.8% (placebo 25%) NCT00292227 · Phase 1 · registry result, not featured evidence | — |
Notes
- aPopulation comparability has not been reviewed for 33 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
rotigotine
show 3 more results
show 3 more results
show 3 more results
+ 80 further endpoints in the CSV export.
Rotigotine (LY03003)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: rotigotine's landscape · Rotigotine (LY03003)'s landscape